m6A-centered Disease Response Information
General Information of the Disease (ID: M6ADIS0084)
| Name |
Energy metabolism disorder
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 5C53
|
||||
Full List of Target Gene(s) of This m6A-centered Disease Response
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2a/ATP2A2)
| In total 1 item(s) under this target gene | ||||
| Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene | [1] | |||
| Response Summary | FTO modification of N6 -methyladenosine is associated with myocardial cell energy metabolism disorder. FTO reduced the m6A level of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2a/ATP2A2) mRNA through demethylation, thus promoting SERCA2a expression, maintaining calcium homeostasis, and improving energy metabolism of H/R cardiomyocytes. | |||
| Responsed Disease | Energy metabolism disorder [ICD-11: 5C53] | |||
| Target Regulator | Fat mass and obesity-associated protein (FTO) | ERASER | ||
| Target Regulation | Up regulation | |||
| Cell Process | Energy metabolism | |||
| Cell apoptosis | ||||
| In-vitro Model | AC16 [Human hybrid cardiomyocyte] | Normal | Homo sapiens | CVCL_4U18 |